269 related articles for article (PubMed ID: 35544598)
21. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
22. Subcellular distribution of Lck during CD4 T-cell maturation in the thymic medulla regulates the T-cell activation threshold.
Stephen TL; Wilson BS; Laufer TM
Proc Natl Acad Sci U S A; 2012 May; 109(19):7415-20. PubMed ID: 22529380
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and pharmacological evaluation of novel benzothiazole derivatives targeting LCK in acute lymphoblastic leukemia.
Chen Y; Zhang K; Tan J; Fan Z; Fu Y; Li X; Liu B; Wang G
Bioorg Chem; 2024 Mar; 144():107180. PubMed ID: 38335758
[TBL] [Abstract][Full Text] [Related]
24. Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion.
Zhang H; Hu Y; Shao M; Teng X; Jiang P; Wang X; Wang H; Cui J; Yu J; Liang Z; Ding L; Han Y; Wei J; Xu Y; Li X; Shan W; Shi J; Luo Y; Qian P; Huang H
J Hematol Oncol; 2021 Jul; 14(1):113. PubMed ID: 34289897
[TBL] [Abstract][Full Text] [Related]
25. The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib.
Morishita T; Hayakawa F; Sugimoto K; Iwase M; Yamamoto H; Hirano D; Kojima Y; Imoto N; Naoe T; Kiyoi H
Oncotarget; 2016 Aug; 7(35):56241-56252. PubMed ID: 27494842
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
[TBL] [Abstract][Full Text] [Related]
27. T cell receptor signal initiation induced by low-grade stimulation requires the cooperation of LAT in human T cells.
Dong S; Corre B; Nika K; Pellegrini S; Michel F
PLoS One; 2010 Nov; 5(11):e15114. PubMed ID: 21152094
[TBL] [Abstract][Full Text] [Related]
28. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
Seggewiss R; Loré K; Greiner E; Magnusson MK; Price DA; Douek DC; Dunbar CE; Wiestner A
Blood; 2005 Mar; 105(6):2473-9. PubMed ID: 15572591
[TBL] [Abstract][Full Text] [Related]
29. Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
Harrington P; Dillon R; Radia D; Rousselot P; McLornan DP; Ong M; Green A; Verde A; Hussain F; Raj K; Kordasti S; Harrison C; De Lavallade H
Haematologica; 2023 Jun; 108(6):1555-1566. PubMed ID: 36700403
[TBL] [Abstract][Full Text] [Related]
30. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of p56(lck) tyrosine kinase by isothiazolones.
Trevillyan JM; Chiou XG; Ballaron SJ; Tang QM; Buko A; Sheets MP; Smith ML; Putman CB; Wiedeman P; Tu N; Madar D; Smith HT; Gubbins EJ; Warrior UP; Chen YW; Mollison KW; Faltynek CR; Djurić SW
Arch Biochem Biophys; 1999 Apr; 364(1):19-29. PubMed ID: 10087161
[TBL] [Abstract][Full Text] [Related]
32. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
[TBL] [Abstract][Full Text] [Related]
33. The lck SH3 domain is required for activation of the mitogen-activated protein kinase pathway but not the initiation of T-cell antigen receptor signaling.
Denny MF; Kaufman HC; Chan AC; Straus DB
J Biol Chem; 1999 Feb; 274(8):5146-52. PubMed ID: 9988764
[TBL] [Abstract][Full Text] [Related]
34. Identification and Characterization of the Amphioxus Lck and Its Associated Tyrosine Phosphorylation-Dependent Inhibitory LRR Receptor.
Zhou J; Xiao Z; Zhan Y; Qu X; Mou S; Deng C; Zhang T; Lan X; Huang S; Li Y
Front Immunol; 2021; 12():656366. PubMed ID: 34149695
[TBL] [Abstract][Full Text] [Related]
35. De novo phosphorylation and conformational opening of the tyrosine kinase Lck act in concert to initiate T cell receptor signaling.
Philipsen L; Reddycherla AV; Hartig R; Gumz J; Kästle M; Kritikos A; Poltorak MP; Prokazov Y; Turbin E; Weber A; Zuschratter W; Schraven B; Simeoni L; Müller AJ
Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096507
[TBL] [Abstract][Full Text] [Related]
36. GM1 controlled lateral segregation of tyrosine kinase Lck predispose T-cells to cell-derived galectin-1-induced apoptosis.
Novák J; Kriston-Pál É; Czibula Á; Deák M; Kovács L; Monostori É; Fajka-Boja R
Mol Immunol; 2014 Feb; 57(2):302-9. PubMed ID: 24231767
[TBL] [Abstract][Full Text] [Related]
37. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
[TBL] [Abstract][Full Text] [Related]
38. The CD45 tyrosine phosphatase regulates specific pools of antigen receptor-associated p59fyn and CD4-associated p56lck tyrosine in human T-cells.
Biffen M; McMichael-Phillips D; Larson T; Venkitaraman A; Alexander D
EMBO J; 1994 Apr; 13(8):1920-9. PubMed ID: 8168490
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia.
Jin Q; Gutierrez Diaz B; Pieters T; Zhou Y; Narang S; Fijalkwoski I; Borin C; Van Laere J; Payton M; Cho BK; Han C; Sun L; Serafin V; Yacu G; Von Loocke W; Basso G; Veltri G; Dreveny I; Ben-Sahra I; Goo YA; Safgren SL; Tsai YC; Bornhauser B; Suraneni PK; Gaspar-Maia A; Kandela I; Van Vlierberghe P; Crispino JD; Tsirigos A; Ntziachristos P
Sci Adv; 2022 Dec; 8(49):eabq8437. PubMed ID: 36490346
[TBL] [Abstract][Full Text] [Related]
40. Update on lymphocyte specific kinase inhibitors: a patent survey.
Martin MW; Machacek MR
Expert Opin Ther Pat; 2010 Nov; 20(11):1573-93. PubMed ID: 20831362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
